Drug Interactions Phase 3: Live Workshop

Image
Drug Interactions Photo Banner

Phase 3 of CAPhO’s Drug Interactions Program is an in-person or virtual, accredited, live Workshop held in conjunction with the CAPhO Conference.

In small groups, you will work through drug interaction cases with the support of expert facilitators. The cases will be typical of clinically relevant drug interactions you will encounter in oncology pharmacy practice. You and your group will make a series of decisions including: interpretation of the drug interaction resource information; prioritization of drug interactions; development of a pharmaceutical care plan including a recommendation, clinical rationale, and communication of your plan; and creation of a patient follow up and/or monitoring plan.

As you will need a basic understanding of several key concepts per case so that you can take advantage of the discussion format that occurs in teams during the Workshop, the authors provide pre-readings and short webinars for you to review before starting the Workshop. Members, view past Workshop Drug Interactions Resources (you need to log in to have access).

The 2022 Drug Interactions Workshop was taken place virtually on Sunday, October 23. 

Workshop Learning Objectives

  1. Assessing patient information and evaluating drug interaction resource materials to identify and prioritize drug interactions commonly seen in oncology practice
  2. Integrating critical thinking and “shared decision making” into drug interaction assessment to develop appropriate recommendations and create suitable monitoring plans
  3. Communicating drug interaction(s) with patients and/or care team providers

Contributors

2022 Online Workshop

Case Authors

  • Ribociclib and QTc Prolongation: Nicole MacDonald, BScPharm, ACPR, Clinical Pharmacist – Medical Oncology, Dr. H Bliss Murphy Cancer Centre – Eastern Health, NL
  • COVID-19 Treatment and Drug Interactions in Oncology: Alisha Shivji, BSc Pharm, ACPR, Tom Baker Cancer Centre, Calgary, Alberta
  • Immune Checkpoint Inhibitor in an Oncology Patient with a Pre-existing Autoimmune Disorder: Tara Leslie, BSP, BCOP, APA, Clinical Pharmacist and Clinical Assistant Professor, Tom Baker Cancer Centre, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta

Case Reviewers

  • Nikki Blosser, BSc. Pharm, ACPR, Tom Baker Cancer Centre, Alberta
  • Nicole Kennedy, BSc. Pharm, PharmD, ACPR, Systemic Therapy Manager of Pharmacy Services, Eastern Health, Newfoundland and Labrador
  • Melanie Danilak, BSc. Pharm, ACPR, MEd, Clinical Practice Leader, Alberta Health Services, Alberta
  • Danica Wasney, B.Sc. Pharm, ACPR, BCOP, Clinical Pharmacist, CancerCare Manitoba, Manitoba

Workshop Facilitators

  • Krista McKinnon, BSc. Pharm,  Alberta Health Services, Alberta
  • Glenn Myers, BScPharm, ACPR, Clinical Oncology Pharmacist, Ambulatory Oncology, Horizon Health Network, New Brunswick
  • Christopher Tse, PharmD, RPh, Princess Margaret Hospital and Toronto General Hospital, Ontario

Webinar Creators

  • Alisha Shivja, BSc Pharm, ACPR, Tom Baker Cancer Centre, Calgary, Alberta
  • Stephanie Lovering, BSc(Hon), BScPhm, PharmD, ACPR, Clinical Pharmacist – Medical Oncology, The Ottawa Hospital, Ontario
  • Jason Wentzell, BScPharm, ACPR, BCOP, MHM, Founder & Oncology Pharmacist Extend Pharmacy
2020 Online Workshop

Case Authors

  • Ribociclib and QTc Prolongation: Nicole MacDonald, BScPharm, ACPR, Clinical Pharmacist – Medical Oncology, Dr. H Bliss Murphy Cancer Centre – Eastern Health, NL
  • Antiretroviral Drug Interactions in Oncology: Marie J. Bravo-Ko, PharmD, RPh, ACPR, Regional Medical Liaison – Hematology/Oncology, Celgene Inc., Mississauga, Ontario
  • Immune Checkpoint Inhibitor in an Oncology Patient with a Pre-existing Autoimmune Disorder: Tara Leslie, BSP, BCOP, APA, Clinical Pharmacist and Clinical Assistant Professor, Tom Baker Cancer Centre, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta

Case Reviewers

  • Melanie Danilak, BSc. Pharm, ACPR, MEd, Clinical Practice Leader, Alberta Health Services, Alberta
  • Danica Wasney, B.Sc. Pharm, ACPR, BCOP, Clinical Pharmacist, CancerCare Manitoba, Manitoba

Workshop Facilitators

  • Kyla Bailey, BSP, Hematology/BMT Clinical Pharmacist – Tom Baker Cancer Centre, Calgary
  • Tara Leslie, BSP, BCOP, APA, Clinical Pharmacist and Clinical Assistant Professor, Tom Baker Cancer Centre, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta
  • Glenn Myers, BScPharm, ACPR, Clinical Oncology Pharmacist, Ambulatory Oncology, Horizon Health Network, New Brunswick

Webinar Creators

  • Stephanie Lovering, BSc(Hon), BScPhm, PharmD, ACPR, Clinical Pharmacist – Medical Oncology, The Ottawa Hospital, Ontario
  • Jason Wentzell, BScPharm, ACPR, BCOP, MHM, Founder & Oncology Pharmacist Extend Pharmacy
2019 Live Workshop

The following CAPhO Members were involved in Phase 3 as Authors, Reviewers and Facilitators in 2019:

Case Authors

  • Proton Pump Inhibitor (PPI) and Tyrosine Kinase Inhibitor (TKI) Interaction: Iryna Knyazevych, BSc, BScPharm, PharmD, Pharmacy Educator, Cross Cancer Institute, Alberta Health Services, Alberta
  • Erlotinib in a Heavy Smoker: Annette Kempston, BScPharm, Pharmacist, Alberta Health Services, CancerControl, Alberta
  • Antiretroviral Drug Interactions in Oncology: Marie Jam Bravo, PharmD, RPh, ACPR, Regional Medical Liaison – Hematology/Oncology, Celgene Inc., Mississauga, Ontario

Case Reviewers

  • Melanie Danilak, BScPharm, ACPR, MEd, Clinical Practice Leader, Alberta Health Services, Alberta
  • Danica Wasney, BScPharm, ACPR, BCOP, Clinical Pharmacist, CancerCare Manitoba, Manitoba

Webinar Creators

  • Sarah Zorzit, BSc, BScPharm, RPh, CDE, Clinical Pharmacist – Outpatient and Retail Pharmacy, Algoma District Cancer Centre, Sault Area Hospital, Ontario
  • Gabriel Gazzé, BScPharm, DPH, BCOP, Pharmacist, Cedars Cancer Center, MUHC- Royal Victoria Hospital, Quebec
  • Louisa Pang, BScPharm, Clinical Pharmacist, BC Cancer, BC

Workshop Facilitators

  • Jennifer Jupp, BScPharm, BCOP, Pharmacy Clinical Practice Leader, Hematology, Oncology, Blood and Marrow Transplant, Alberta Health Services - Calgary Zone, Alberta
  • Tara Leslie, BSP, BCOP, APA, Clinical Pharmacist and Clinical Assistant Professor, Tom Baker Cancer Centre, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta
  • Glenn Myers, BScPharm, ACPR, Clinical Oncology Pharmacist, Ambulatory Oncology, Horizon Health Network, New Brunswick
2018 Live Workshop

The following CAPhO Members were involved in Phase 3 as Authors, Reviewers and Facilitators in 2018.

Authors

  • QT Prolongation: Maria Anwar, BScPharm, ACPR, Clinical Practice Leader, Alberta Health Services, Alberta
  • How much natural is too much natural?: Mark Diachinsky, BScPharm, Clinical Practice Leader, North Zone, Pharmacy Services, Alberta Health Services, Alberta
  • Pharmacokinetic Drug Interaction: Erin Francis, BSc, BScPharm, ACPR, Pharmacist – Blood and Marrow Transplant and Gynecologic Oncology, Pharmacy Department, The Ottawa Hospital, Ontario
  • Proton Pump Inhibitor (PPI) and Tyrosine Kinase Inhibitor (TKI) Interaction: Iryna Knyazevych, BSc, BScPharm, PharmD, Pharmacy Educator, Cross Cancer Institute, Alberta Health Services, Alberta

Reviewers

  • Melanie Danilak, BScPharm, ACPR, MEd, Pharmacy Clinical Practice Leader, Alberta Health Services, Alberta
  • Marcel Romanick, BScPharm, Clinical Practice Leader, Pharmacy Services, Alberta Health Services, Alberta

Facilitators

  • Tara Leslie, BSP, BCOP, Clinical Pharmacist and Clinical Assistant Professor, Tom Baker Cancer Centre, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta
  • Glenn Myers, BScPharm, ACPR, Clinical Oncology Pharmacist, Ambulatory Oncology, Horizon Health Network, New Brunswick
  • Tiffany Nguyen, BScPharm, ACPR, BCOP, Clinical Pharmacist, Bone Marrow Transplant Program, The Ottawa Hospital, Ontario
  • Jason Wentzel, BScPharm, ACPR, BCOP, Clinical Pharmacist, Medical Oncology, The Ottawa Hospital, Ontario

Facilitator Manual Creators

  • Tara Leslie, BSP, BCOP, Clinical Pharmacist and Clinical Assistant Professor, Tom Baker Cancer Centre, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta
  • Glenn Myers, BScPharm, ACPR, Clinical Oncology Pharmacist, Ambulatory Oncology, Horizon Health Network, New Brunswick

Curriculum Plan Development

  • Tara Leslie, BSP, BCOP, Clinical Pharmacist and Clinical Assistant Professor, Tom Baker Cancer Centre, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta

Accreditation

CCCEP accreditation

The Canadian Council on Continuing Education in Pharmacy (CCCEP) is a national organization established to accredit continuing pharmacy education programs intended to be delivered to pharmacy professionals from more than one province or nationally. CCCEP accreditation is recognized by the pharmacy regulatory authorities in all provinces and territories of Canada.

  • 2020: 4.2 CEUs
  • 2019:  4.17 CEUs
  • 2018:  4.2 CEUs